Drug Type Antibody fusion proteins |
Synonyms HY-0007, HY07121 |
Action agonists, modulators, inhibitors |
Mechanism IL-15 agonists(Interleukin-15 agonists), IL-15Rα modulators(Interleukin-15 receptor subunit alpha modulators), PD-1 inhibitors(Programmed cell death protein 1 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 1/2 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Advanced Malignant Solid Neoplasm | Phase 2 | China | 17 Oct 2024 | |
Kidney Neoplasms | Preclinical | China | 01 Dec 2022 | |
Melanoma | Preclinical | China | 01 Dec 2022 | |
Non-Small Cell Lung Cancer | Preclinical | China | 01 Dec 2022 | |
Ovarian Cancer | Preclinical | China | 01 Dec 2022 | |
Small Cell Lung Cancer | Preclinical | China | 01 Dec 2022 |